Phibro Animal Health (PAHC) Total Non-Current Liabilities (2013 - 2026)
Phibro Animal Health's (PAHC) quarterly Total Non-Current Liabilities came in at $1.1 billion in Q1 2026, up 4.13% year-on-year from $1.0 billion in Q1 2025, and up 1.82% quarter-over-quarter from $1.1 billion in Q4 2025.
Phibro Animal Health (PAHC) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Phibro Animal Health's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 4.13% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 4.13% increase from a year earlier, with the FY2025 full-year figure at $995.9 million, up 38.57% from the prior year.
- Total Non-Current Liabilities rose to $1.1 billion in Q1 2026 per PAHC's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.1 billion in Q1 2026 and bottomed at $608.8 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $694.8 million (2023), against an average of $798.6 million.
- Across the five-year window, Total Non-Current Liabilities retreated 1.89% in 2023 and surged 61.08% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $684.3 million in 2022, then climbed by 1.53% to $694.8 million in 2023, then surged by 47.81% to $1.0 billion in 2024, then increased by 3.48% to $1.1 billion in 2025, then climbed by 1.82% to $1.1 billion in 2026.
- Per Business Quant, the three latest PAHC Total Non-Current Liabilities figures stand at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $994.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Phibro Animal Health | 1.38 Bn | 1.30 Bn | 125.68 Mn | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 994.66 Mn |
| Jun 30, 2025 | 995.91 Mn |
| Mar 31, 2025 | 1.04 Bn |
| Dec 31, 2024 | 1.03 Bn |
| Sep 30, 2024 | 701.27 Mn |
| Jun 30, 2024 | 718.70 Mn |
| Mar 31, 2024 | 645.08 Mn |
| Dec 31, 2023 | 694.77 Mn |
| Sep 30, 2023 | 685.36 Mn |
| Jun 30, 2023 | 682.81 Mn |
| Mar 31, 2023 | 631.32 Mn |
| Dec 31, 2022 | 684.29 Mn |
| Sep 30, 2022 | 679.71 Mn |
| Jun 30, 2022 | 608.76 Mn |
| Mar 31, 2022 | 643.51 Mn |
| Dec 31, 2021 | 553.95 Mn |
| Sep 30, 2021 | 546.60 Mn |
| Jun 30, 2021 | 546.83 Mn |